Duchenne muscular dystrophy (DMD) is an X-linked muscle disorder characterized by progressive and irreversible loss of muscular function. As muscular disease progresses, the repair mechanisms cannot compensate for cellular damage, leading inevitably to necrosis and progressive replacement by fibrous and fatty tissue. Cardiomyopathy and respiratory failure are the main causes of death in DMD. In addition to the well-described muscle and heart disease, cognitive dysfunction affects around 30% of DMD boys. Myocardial fibrosis, assessed by late gadolinium enhancement (LGE), using cardiovascular magnetic resonance imaging (CMR), is an early marker of heart involvement in both DMD patients and female carriers. In parallel, brain MRI identifies smaller total brain volume, smaller grey matter volume, lower white matter fractional anisotropy and higher white matter radial diffusivity in DMD patients. The in vivo brain evaluation of mdx mice, a surrogate animal model of DMD, showed an increased inorganic phosphate (P(i))/phosphocreatine (PCr) and pH. In this paper, we propose a holistic approach using techniques of magnetic resonance imaging, spectroscopy and diffusion tensor imaging as a tool to create a "heart and brain imaging map" in DMD patients that could potentially facilitate the patients' risk stratification and also future research studies in the field.
| INTRODUCTION
Duchenne muscular dystrophy (DMD) is an X-linked muscle disorder characterized by progressive and irreversible loss of muscular function. [1] [2] [3] This is due to lack of dystrophin, a large membrane-associated protein expressed in striated muscles, heart and brain. 4, 5 The incidence of DMD is 1 in 3500 male newborns with a prevalence of 6 in 100 000 males. 6 DMD is characterized by progressive weakness of the legs, pelvic and shoulder muscles that starts in early childhood.
Dystrophin is a component of the dystrophin-glycoprotein complex that serves as a connection between the large complex of glycoproteins in the muscle cell membrane and intracellular actin filaments and is in charge of transmitting forces generated by sarcomere contraction to the extracellular matrix. 7, 8 Absence, reduced levels or abnormal structure of dystrophin causes membrane fragility and makes muscle fibres prone to contraction injury. 9 In DMD, as muscular damage progresses, repair mechanisms cannot compensate for the ongoing cellular damage, leading inevitably to necrosis of skeletal and cardiac myocytes and progressive replacement by fibrous and fatty tissue. 10 While in DMD, respiratory muscle failure is the commonest cause of death, in Becker muscular dystrophy (BMD), a milder form of muscular dystrophy, the prognosis mainly depends on the development of cardiomyopathy. Most of DMD patients that survive from respiratory dysfunction will finally develop cardiomyopathy. 11 However, in these patients, clinically overt heart failure may be absent, due to relative physical inactivity. Cardiovascular magnetic resonance imaging (CMR) can detect myocardial tissue lesions before the decline in left ventricular (LV) systolic function. The severity and the evolution of cardiomyopathy do not correlate with the type of dystrophin mutation. 12 In DMD with preserved LV ejection fraction, the addition of eplerenone to angiotensin-convertingenzyme inhibitors (ACEI) or angiotensin II receptor blocker (ARB) attenuates the progressive decline in LV systolic function. 13 In female DMD carriers, cardiac disease may present with hypertrophy, arrhythmias or dilated cardiomyopathy.
14 Development of significant cardiac disease is unusual in female carriers younger than 16 years of age. 15 However, clinically overt cardiac disease increases by age, from 15% in carriers <16 years to 45% in carriers >16 years. In a study of 85 DMD and 44 BMD adult carriers, dilated cardiomyopathy was documented in 18% and 8%, respectively 16 ; yes ECG changes were documented in only 47%. 17 In another series of 56 adult female carriers without ECG changes, cardiac ventricular dilatation or hypertrophy was documented in 14% and dilated cardiomyopathy in 7%. 18 Of note, there are reports of severe heart failure in female carriers requiring heart transplantation. 19, 20 Furthermore, in some female carriers with normal rest LV function, LV systolic dysfunction can be detected during exercise. 21 Our group, by using CMR, documented myocardial fibrosis in the majority of DMD mother-carriers; however, the clinical presentation and the usual noninvasive assessment were normal or mildly abnormal. 22 These findings lead to the recommendation of a detailed cardiac evaluation in all female carriers after the teenage years, in order to start cardiac medication as earlier as possible. 23 Angiotensin-converting-enzyme inhibitors have been proved effective in the prevention of LV remodelling in ischaemic cardiomyopathy by reducing LV hypertrophy and fibrosis leading to ventricular arrhythmias and sudden cardiac death (SCD). 24 Early initiation of treatment with perindopril in DMD patients with normal LV ejection fraction was associated with lower mortality. 25 Other studies documented that a beta-noradrenergic blocker (BB), in addition to ACEI, improves LV systolic function in DMD patients. These encouraging results strongly support the initiation of ACEI and/or BB early in the course of the disease. 25, 26 Screening and therapy of arrhythmias is also crucial in DMD. In advanced DMD cardiomyopathy, cardiac arrhythmias include atrial fibrillation/flutter, ventricular tachycardia and ventricular fibrillation. The presence of late gadolinium enhancement (LGE) in postcontrast T1-w CMR images was associated with increased arrhythmia risk in DMD. 27 In such patients with an LV ejection fraction < 35%, the heart failure guidelines for primary arrhythmia prevention and the risk/benefit ratio should be seriously considered. However, the risk of intervention may be greater in advanced DMD, because severe kyphoscoliosis and respiratory muscle weakness may increase the risks associated with implantable cardioverterdefibrillator (ICD) define implantation. The use of biventricular pacing in DMD has not been assessed yet. However, the pattern of inferolateral fibrosis assessed by CMR even in the early stages of DMD patients is similar to the pattern associated with lack of response to resynchronization therapy in the general heart failure population 28 .
In addition to the well-described muscle and heart disease, some DMD patients have also cognitive dysfunction. In the original description of the disease in 1861, Duchenne reported 5 patients with cognitive defects. 29 There are also some published studies about cognitive dysfunction in DMD patients 30, 31 ; additionally, mental retardation affects around 30% of boys with DMD. 32 Impaired memory function, especially restricted verbal short-term memory, characterizes the neuropsychological behaviour of many DMD patients. 33, 34 Language impairments, long-term memory problems and limited executive functions have been reported. 35, 36 Finally, in mdx mice, behavioural studies have also documented learning impairments. 37, 38 Dystrophin is normally expressed at the level of postsynaptic neuronal terminals of the brain cortex, hippocampus and cerebellum areas, regions that play an important role in reasoning, memory and learning. 39 However, the precise function of dystrophin in the brain remains still unknown. 40 Cognitive impairment in DMD patients is probably related to the reduced levels of dystrophin in the central nervous system (CNS); 41 in skeletal and cardiac muscles, dystrophin plays both functional and structural roles by (i) supporting the sarcolemma against mechanical stress, 42 (ii) taking part in the regulation of intracellular calcium and calcium-related events, 43, 44 (iii) involved in signal transduction, 45 (iv) influencing the aggregation of neurotransmitter receptors 46, 47 and (v) preventing excessive generation of reactive oxygen free radical species. 48, 49 Furthermore, DMD and BMD patients due to dysfunctional dystrophin are deficient in neuronal nitric oxide synthase (nNOS) in both muscles and the brain. Therefore, nNOS, which is important for the regulation of microvascular circulation in the brain, may participate in the CNS manifestations of DMD and BMD. 50 Identifying the role of brain dystrophin would be extremely helpful in the era of new therapeutic approaches for DMD. 50 2 | MRI FOR HEART, MUSCLES AND BRAIN
| Cardiovascular magnetic resonance
Cardiovascular magnetic resonance is a noninvasive technique, using nonionizing radiation, ideal for the evaluation of cardiac volumes, mass, ejection fraction, inflammation and fibrosis in DMD. 51 Furthermore, it is operator independent with excellent reproducibility; these characteristics are of great value for the serial assessment of DMD patients. [52] [53] [54] Strain analysis can be an early, preclinical finding in DMD, before any other cardiac index can be influenced. DMD patients, evaluated by CMR tagging, had abnormal global and segmental circumferential strain, compared with age-and sex-matched controls, despite similar LV volumes and ejection fraction. 55 We should mention that the abnormal myocardial strain usually precedes both the age-dependent impairment of LV function and the myocardial fibrosis in DMD. 55 Finally, strain analysis was more sensitive to detect serial changes of LV function, compared with LVEF, 56 and therefore, it is an excellent tool to evaluate treatment efficacy. However, these indices, although promising, do not represent a robust tool for the detection of cardiac involvement in DMD and are not widely acceptable.
The most robust CMR data for the early detection of cardiac lesions in DMD are referred to early myocardial fibrosis in these patients and female carriers, detected by LGE. Cardiomyopathy in dystrophinopathies includes the presence of subepicardial fibrosis in the inferolateral wall, 54, 57 similar to that observed in viral myocarditis.
CMR in DMD, in addition to the standard monitoring by echocardiography and ECG, is of great value because: (i) the early start of heart failure treatment may delay or even reverse the progression of LV dysfunction 58 and (ii) myocardial fibrosis, assessed by LGE, can be documented, even if the echocardiographic evaluation is still normal.
57,59
Therefore, CMR can serve as a sensitive index for an early start of cardioprotective treatment in these patients, or serve as a screening tool to detect patients at high risk for ventricular arrhythmias or sudden death, more advanced disease and adverse LV remodelling 27 ( Figures 1 and 2 ).
Finally, CMR with LGE and wall motion analysis is superior to transthoracic echocardiography (TTE) and tissue Doppler (TD) in early assessment of myocardial damage in dystrophinopathies. ECG and heart rate variability (HRV) abnormalities, although common in DMD patients, are not predictive of segmental and global LV dysfunction. 60 In DMD carriers, CMR can reveal a pattern of fibrosis similar to that observed in DMD patients 22 ( Figure 3) , even in the absence of overt muscular disease. Recently, CMR techniques, such as postcontrast myocardial T1 mapping, have been applied in DMD patients to detect diffuse myocardial fibrosis. 61 Unfortunately, measurement of laboratory indices, such as NT-pro BNP in DMD patients and carriers, cannot discriminate between those with and without cardiomyopathy. 
| Muscle MRI
Quantitative muscle MRI can measure the fat replacement of skeletal muscle by either chemical shift imaging method (Dixon or IDEAL), or spectroscopy can provide sensitive, objective measurements. 63 In another MRI study, fatty infiltration and oedema were detected in the upper arm skeletal muscles but not in the myocardium in DMD patients. The authors suggested that imaging the heart and skeletal muscle using the same magnetic resonance methods during a single scan may be useful to assess relative disease status and therapeutic response in clinical trials 64 .
| Brain magnetic resonance imaging/ spectroscopy (BMRI/BMRS) and diffusion tensor imaging (DTI)
Brain MRI can give valuable information about the structural and functional brain status in DMD patients. In a recent study, DMD patients who performed worse than controls on neuropsychological examination, 50 on neuroimaging evaluation, had smaller total brain volume, smaller grey matter volume, lower white matter fractional anisotropy, higher white matter mean and radial diffusivity than healthy controls 65, 66 Subgroup analyses showed that DMD_Dp140(-) subjects contributed most to the grey matter volume differences and performed worse on information processing.
67
31P-magnetic resonance spectroscopy (MRS) has already shown in vivo various abnormalities within skeletal muscle of mdx mice and DMD boys. The in vivo brain evaluation of mdx mice showed an increased inorganic phosphate (P(i))/phosphocreatine (PCr) ratio and elevated pH compared with controls, and biochemical analysis showed a reduction in total creatine, increased extracellular and decreased intracellular volume. It has been proposed that these biochemical changes may be a factor for the reduced cognitive capacity of mdx mice and some DMD children. 67 The same study also documented that DMD brain had 31P-MRS abnormalities in vivo similar to those found in DMD muscle, suggesting that cognitive dysfunction in DMD may be related to an altered metabolism. 66 In a recent study, it was shown that there is an enlargement of the lateral ventricles of the brain in mdx mice when compared to controls. 68 Diffusion tensor imaging is an MRI technique that measures diffusion of water molecules along the axons of bundles of neurons in a series of different spatial directions. This method determines from the shape and orientation of the diffusion ellipsoid at each image pixel by fitting the MRI data to the ellipsoid describing best the local axonal architecture. Therefore, DTI can measure the axonal and myelin integrity, as well as the neuronal density in the white matter. The DTI scan can provide a series of qualitative information regarding neurons: firstly, 2-dimensional colour-coded orientation maps of neuronal bundles, where the intensity is a function of the anisotropy information and 3 major colours, red, green and blue, representing neuronal fibres running along the left-right, anterior-posterior and superior-inferior axes, respectively, as well as quantitative information, such as fractional anisotropy. The fractional anisotropy index is deduced by placing a ROI define upon a bundle of neurons. The derived number is unitless and represents the density and integrity of the neuronal axons and their myelin membrane. It ranges between zero (0), ie, no bundles of neurons, and one (1), ie, high structural integrity of neuronal bundles.
Diffusion tensor imaging revealed elevations in diffusivities in the prefrontal cortex and a reduction in fractional anisotropy in the hippocampus. Metabolic changes included elevations in phosphocholine and glutathione, and a reduction in c-aminobutyric acid in the hippocampus. In addition, an elevation in taurine was observed in the prefrontal cortex. Such findings indicated a regional structural change, altered cellular antioxidant defences, a dysfunction of GABAergic neurotransmission and a perturbed osmoregulation in the brain lacking dystrophin. 68 Diffusion tensor imaging data on young patients with DMD showed interesting results that correlate cognitive deficits with microstructural neuronal variations. First, qualitative results of fractional anisotropy images showed a deficit of neurons in various neuroanatomic areas of the two hemispheres ( Figure 3) . Second, quantitative measurements, where various ROIs have been placed bilaterally in various neuroanatomic areas such as parietal, frontal, occipital, temporal lobes, genu, splenium of the corpus callosum, caudate nuclei, anterior and posterior cingulate, lenticular nuclei, anterior and posterior limb of the internal capsule, hippocampus, superior and middle cerebellar peduncle and thalamus, showed similar lesions; in DTI coloured maps, their corresponding fractional anisotropy showed numerically a neuronal deficit (Figures 4 and 5) . 69, 70 3 | CONCLUSIONS Duchenne muscular dystrophy is a complex disease that involves not only the striated muscles, but also the heart and the brain. A holistic approach by magnetic resonance imaging/spectroscopy may lead to an individual "heart and brain imaging map", facilitate risk stratification, serial follow-up and treatment evaluation, and serve as a reliable tool for future clinical trials in DMD patients.
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